Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : BAL0891,Carboplatin
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : SillaJen, Inc
Deal Size : Undisclosed
Deal Type : Collaboration
OSR Holdings and SillaJen Sign MOU to Develop Innovative Therapeutics in US Market
Details : The collaboration will explore various ways to create synergies between current platform technologies and new drug candidates, including BAL0891, a mitotic checkpoint inhibitor targeting solid tumors.
Product Name : BAL0891
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 22, 2024
Lead Product(s) : BAL0891,Carboplatin
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : SillaJen, Inc
Deal Size : Undisclosed
Deal Type : Collaboration